Hello, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that all-too-familiar routine of deadlines, meetings, and the like has returned. Never mind that this is midsummer — the world continues to spin. And this means the time has come to get cracking. And so, we bring you the usual menu of tidbits to help you along. Hope you have a smashing day and do keep in touch. We enjoy your tips and stories …
Teva Pharmaceuticals (TEVA) may have to bust its piggy bank to lure candidates to help reverse its sagging fortunes, The Wall Street Journal says. The world’s biggest generic drug maker lost a quarter of its market value last Thursday after missing earnings, cutting profit guidance, and slashing its dividend thanks to pricing pressures. Erez Vigodman, the previous chief executive who left in February, received $5.3 million in salary and equity shares last year.
About the Author Reprints
Don’t count your chickens, Ms Walmsley. Heather Bresch didn’t have any baggage either at the outset.